FDA guidance
Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and…
FDA guidance · Draft · issued Sep 18, 2023
Key facts
| Title | Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act (Revision 1): Draft Guidance for Industry |
|---|---|
| Status | Draft |
| Issue date | Sep 18, 2023 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Biologics, Drugs |
| Docket number | FDA-2011-D-0611 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents